Which has the lower trailing P/E, CORT or JAZZ?

JAZZ has the lower trailing P/E: CORT trades at 284.69 and JAZZ at 15.82. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, CORT or JAZZ?

Over the past five years, CORT grew revenue faster — CORT at a 19.35% CAGR versus JAZZ at 11.87%.

Is CORT or JAZZ more profitable?

JAZZ runs the higher net margin — CORT at 6.61% versus JAZZ at 20.45%.

How have CORT and JAZZ total returns compared?

Over the past 10 years, CORT delivered 33.70% and JAZZ delivered 6.58% annualized total return. Past performance doesn't predict future results.

Corcept Therapeutics Incorporated (CORT) vs Jazz Pharmaceuticals plc (JAZZ)

A side-by-side comparison of Corcept Therapeutics Incorporated and Jazz Pharmaceuticals plc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CORT

Corcept Therapeutics Incorporated

$12.93B

$119.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

JAZZ

Jazz Pharmaceuticals plc

$14.54B

$231.39HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — CORT vs JAZZ

growth of $100 · dividends reinvested · last 10y

CORT +1837.0% (+34.5%/yr)JAZZ +92.0% (+6.7%/yr)CORT compounded faster over this window

Log scale — wide-divergence pair

CORT JAZZ

CORT vs JAZZ: by the numbers

•JAZZ is the larger company ($14.54B vs $12.93B market cap).
•JAZZ trades at the lower trailing earnings multiple (15.82 vs 284.69 P/E), one valuation lens rather than an overall verdict.
•JAZZ converts more revenue to profit (20.45% vs 6.61% net margin).
•CORT grew revenue faster over the past five years (19.35% vs 11.87% CAGR).

Metrics side by side

Valuation

Metric	CORT	JAZZ
P/E ratio	284.69	15.82
Forward P/E	N/A	9.27
P/S ratio	15.56	3.16
P/B ratio	18.31	3.03
EV / EBITDA	1453.11	8.74
FCF yield	0.83%	10.61%

Profitability

Metric	CORT	JAZZ
Gross margin	98.30%	84.67%
Operating margin	0.77%	5.26%
Net margin	6.61%	20.45%
ROE	7.78%	19.59%
ROIC	0.87%	14.48%

Growth (annualized)

Metric	CORT	JAZZ
Revenue CAGR (5Y)	19.35%	11.87%
EPS CAGR (5Y)	0.64%	N/A
FCF CAGR (5Y)	-4.40%	15.39%
Total return CAGR (5Y)	43.90%	13.01%

Frequently asked

Which has the lower trailing P/E, CORT or JAZZ?: JAZZ has the lower trailing P/E: CORT trades at 284.69 and JAZZ at 15.82. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, CORT or JAZZ?: Over the past five years, CORT grew revenue faster — CORT at a 19.35% CAGR versus JAZZ at 11.87%.
Is CORT or JAZZ more profitable?: JAZZ runs the higher net margin — CORT at 6.61% versus JAZZ at 20.45%.
How have CORT and JAZZ total returns compared?: Over the past 10 years, CORT delivered 33.70% and JAZZ delivered 6.58% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CORT analysis Full JAZZ analysis Interactive comparison tool

Dig into the metrics

Corcept Therapeutics P/E ratio Jazz Pharmaceuticals P/E ratio Corcept Therapeutics ROE Jazz Pharmaceuticals ROE Corcept Therapeutics operating margin Jazz Pharmaceuticals operating margin Corcept Therapeutics revenue growth Jazz Pharmaceuticals revenue growth Corcept Therapeutics free cash flow Jazz Pharmaceuticals free cash flow

Corcept Therapeutics & Jazz Pharmaceuticals appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.